Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 337

Drugs for the K-Ras oncogene inspire an approach for targeting the GTPases, a family of enzymes whose dysfunction can lead to Parkinson’s and many other diseases.

UCSF scientists have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases from Parkinson’s to cancer and have long been thought to be “undruggable.”

Because of their slippery exteriors, the GTPases have remained largely out of reach of modern drug discovery, with the exception of the notorious cancer-causing GTPase called K-Ras.

Read more | >

The foundation hopes to prevent extinctions, and obtain the necessary biological material to safeguard genetic diversity.

Already backed by a confirmed $50 million in funding, its goal is to halt the extinction crisis through three key conservation focus points.

The Colossal Foundation’s first key…

Who ever said you can’t save a few species on the way to de-extincting a mammoth?

Read more | >

Researchers from the Color and Food Quality group at the Faculty of Pharmacy, University of Seville, in partnership with Dr. Marina Ezcurra’s team at the University of Kent (UK), have demonstrated that the carotenoid phytoene extends the lifespan of the nematode Caenorhabditis elegans. Additionally, it delays the onset of paralysis linked to amyloid plaque formation in an Alzheimer’s disease model.

Specifically, increases in longevity of between 10 and 18.6% and decreases in the proteotoxic effect of plaques of between 30 and 40% were observed. The studies, which form part of Ángeles Morón Ortiz’s doctoral thesis, tested pure phytoene and extracts rich in this carotenoid obtained from microalgae.

According to Dr. Paula Mapelli Brahm, “These are very exciting preliminary results, so we are looking for funding to continue this line of research and to find out by what mechanisms these effects are produced.”

Read more | >

The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.

Announced today, the award to a multi-institutional team of researchers, including Carnegie Mellon University, will fast-track development and testing of a new approach to cancer treatment that aims to dramatically improve immunotherapy outcomes for patients with ovarian, pancreatic, and other difficult-to-treat cancers.

schematic of the implant technology
Source: Brandon Martin/Rice University. The “hybrid advanced molecular manufacturing regulator,” or HAMMR, a “closed-loop,” drug-producing implant smaller than an adult’s finger is being developed to treat ovarian, pancreatic, and other difficult-to-treat cancers. The implant, which is small enough to be implanted with minimally-invasive surgery, will be able to continuously monitor a patient’s cancer and adjust their immunotherapy dose in real time.

Read more | >

The chapter summarizes the current information available from a variety of scientifically based guidelines and resources on dietary advice for those with diabetes. It is a practical overview for health care practitioners working in diabetes management. The chapter is divided into sections by content and includes sources for further reading. A primary message is that nutrition plans should meet the specific needs of the patient and take into consideration their ability to implement change. Often starting with small achievable changes is best, with larger changes discussed as rapport builds. Referral to medical nutrition therapy (MNT) provided by a Registered Dietitian Nutritionist (RDN) and a diabetes self-management education and support (DSMES) program is highlighted. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

Read more | >